Photo of Shubh Goel taken from LinkedIn
Feb 27, 2024, 05:27
Shubh Goel: Recently, I spoke to a Pharmaceutical Executive following data presented at ASCO GI from our EMERALD-1 and MATTERHORN Phase III trials
Shubh Goel, VP and US Franchise Head, Immuno-Oncology and GI Tumors at
“This post is intended for a US audience. Recently, I spoke to a Pharmaceutical Executive following data presented at ASCO GI from our EMERALD-1 and MATTERHORN Phase III trials, in liver cancer and gastric cancer, respectively.
At AstraZeneca, we believe if we can intervene earlier, we have a better chance of improving long-term outcomes for patients, so it was great to share more about our extensive clinical development program to treat GI cancers earlier. Thanks for chatting with me, Donald Tracy!”
Source: Shubh Goel/LinkedIn
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 14, 2024, 00:19
Nov 14, 2024, 00:02
Nov 13, 2024, 23:57
Nov 13, 2024, 23:54
Nov 13, 2024, 23:48
Nov 13, 2024, 23:46